key: cord-0798616-5xrtuc06
authors: Papadopoulos, Konstantinos I; Sutheesophon, Warachaya; Manipalviratn, Somjate; Aw, Tar-Choon
title: Age and genotype dependent erythropoietin protection in COVID-19
date: 2021-10-26
journal: World J Stem Cells
DOI: 10.4252/wjsc.v13.i10.1513
sha: dad7c6b92e7244b16a05f73597b8a7c0371412b3
doc_id: 798616
cord_uid: 5xrtuc06

Erythropoietin (EPO) is the main mediator of erythropoiesis and an important tissue protective hormone that appears to mediate an ancestral neuroprotective innate immune response mechanism at an early age. When the young brain is threatened-prematurity, neonatal hyperbilirubinemia, malaria- EPO is hyper-secreted disproportionately to any concurrent anemic stimuli. Under eons of severe malarial selection pressure, neuroprotective EPO augmenting genetic determinants such as the various hemoglobinopathies, and the angiotensin converting enzyme (ACE) I/D polymorphism, have been positively selected. When malarial and other cerebral threats abate and the young child survives to adulthood, EPO subsides. Sustained high ACE and angiotensin II (Ang II) levels through the ACE D allele in adulthood may then become detrimental as witnessed by epidemiological studies. The ubiquitous renin angiotensin system (RAS) influences the α-klotho/fibroblast growth factor 23 (FGF23) circuitry, and both are interconnected with EPO. Here we propose that at a young age, EPO augmenting genetic determinants through ACE D allele elevated Ang II levels in some or HbE/beta thalassemia in others would increase EPO levels and shield against coronavirus disease 2019, akin to protection from malaria and dengue fever. Human evolution may use ACE2 as a “bait” for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to gain cellular entry in order to trigger an ACE/ACE2 imbalance and stimulate EPO hypersecretion using tissue RAS, uncoupled from hemoglobin levels. In subjects without EPO augmenting genetic determinants at any age, ACE2 binding and internalization upon SARS-CoV-2 entry would trigger an ACE/ACE2 imbalance, and Ang II oversecretion leading to protective EPO stimulation. In children, low nasal ACE2 Levels would beneficially augment this imbalance, especially for those without protective genetic determinants. On the other hand, in predisposed adults with the ACE D allele, ACE/ACE2 imbalance, may lead to uncontrolled RAS overactivity and an Ang II induced proinflammatory state and immune dysregulation, with interleukin 6 (IL-6), plasminogen activator inhibitor, and FGF23 elevations. IL-6 induced EPO suppression, aggravated through co-morbidities such as hypertension, diabetes, obesity, and RAS pharmacological interventions may potentially lead to acute respiratory distress syndrome, cytokine storm and/or autoimmunity. HbE/beta thalassemia carriers would enjoy protection at any age as their EPO stimulation is uncoupled from the RAS system. The timely use of rhEPO, EPO analogs, acetylsalicylic acid, bioactive lipids, or FGF23 antagonists in genetically predisposed individuals may counteract those detrimental effects.

Erythropoietin (EPO) is the main mediator of erythropoiesis and an important tissue protective hormone that appears to mediate an ancestral neuroprotective innate immune response mechanism at an early age. When the young brain is threatened-prematurity, neonatal hyperbilirubinemia, malaria-EPO is hypersecreted disproportionately to any concurrent anemic stimuli. Under eons of severe malarial selection pressure, neuroprotective EPO augmenting genetic determinants such as the various hemoglobinopathies, and the angiotensin converting enzyme (ACE) I/D polymorphism, have been positively selected. When malarial and other cerebral threats abate and the young child survives to adulthood, EPO subsides. Sustained high ACE and angiotensin II (Ang II) levels through the ACE D allele in adulthood may then become detrimental as witnessed by epidemiological studies. The ubiquitous renin angiotensin system (RAS) influences the α-klotho/fibroblast growth factor 23 (FGF23) circuitry, and both are interconnected with EPO. Here we propose that at a young age, EPO augmenting genetic determinants through ACE D allele elevated Ang II levels in some or HbE/beta thalassemia in others would increase EPO levels and shield against coronavirus disease 2019, akin to protection from malaria and dengue fever. Human evolution may use ACE2 as a "bait" for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to gain cellular entry in order to trigger an ACE/ACE2 imbalance and stimulate EPO hypersecretion using tissue RAS, uncoupled from hemoglobin levels. In subjects without EPO augmenting genetic

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease of 2019 pandemic (COVID-19) has to date (September 11, 2021) infected almost 225 million people worldwide, causing nearly 4.6 million deaths [1] . The COVID-19 pandemic continues to be a global threat despite increasing vaccinations[1]. We and others have recently proposed that the thalassemias and especially HbE, might confer resistance to and/or protection from SARS-CoV2 infection and severity [2, 3] . Supporting this hypothesis, Littera et al [4] from Sardinia found none of their seriously ill COVID-19 patients were carriers of beta-thalassemia while a recent metanalysis reported a pooled incidence rate of COVID-19 in patients with beta thalassemia at 1.34 per 100000 personday, which is less than half of that observed in the general population (2.89) [5] . We hypothesized that host immune system modulations engendered by malarial selection pressure via thalassemia/HbE mutations might confer this protection akin to an antimalarial effect [2] . Another genetic variant significantly associated with mild malaria vs severe malaria is the D allele of angiotensin converting enzyme (ACE) I/D polymorphism, that codes for higher ACE levels and subsequently increased angiotensin II (Ang II) production vs the I allele[6-8]. We attempted, therefore, to trace a common denominator to explain the emergence of those two genetic determinants forced by malarial evolutionary pressure. We posit here that the evolutionary selection of thalassemias and the ACE D allele as adaptive alleles for pathogen resistance is neither coincidental nor surprising. Both genetic determinants appear to elicit and sustain a phylogenetically preserved ancestral neuroprotective innate immune response mechanism against tissue injury or pathogen invasion mediated either via systemic or/and local increases in erythropoietin (EPO) production [9] .

In the present review, we will attempt to explain how (1) Elevated EPO can account for COVID-19 protection in the young; (2) EPO augmenting genetic determinants can predispose for severe COVID-19 complications in adults, and (3) Endogenous and/or pharmacological EPO modulation may offer innovative approaches to treat and/or mitigate SARS-CoV-2 disease severity.

EPO is an evolutionary conserved hormone, well known for almost a century as the main mediator of erythropoiesis but its widespread effects throughout the body might transcend its primary role[9]. EPO's principal physiologic stimulus for secretion is tissue hypoxia which upon detection by renal interstitial cells is subsequently secreted [9] . Apart from its two main sites of secretion, the kidney and liver, EPO is locally produced and released in a paracrine or autocrine fashion by cells of various tissues including the heart, lungs, testes, ovaries, enterocytes, breast gland and human milk, spleen, bone marrow macrophages, placenta, retina, astrocytes, and neurons[10,11]. EPO's erythropoietic effects are mediated via binding to an EPO receptor (EPOR) homodimer (EPOR) 2 on erythroid precursors [9] . Evidence supports the renin angiotensin system (RAS) system via Ang II and the EPO-fibroblast growth factor 23 (FGF23) signaling pathway as additional regulatory pathways, possibly involved in EPO's non-hematological functions[12,13]. EPO's two distinctive activities (erythropoiesis and tissue protection) appear to reside in different EPO domains and bind to two distinct receptors [14] .

When pathogen invasion, tissue trauma or insult occurs, a defensive strategic ensemble is summoned, spearheaded by chemokines and inflammatory cytokines, to attract armies of immune cells that fend off, isolate, kill and remove pathogens and dead cells. This process needs to be controlled and must not be allowed to propagate. Thus, a tissue protective mechanism is required and seems to be provided by the presence of EPO via its binding to the tissue-protective receptor (TPR), a heteromeric complex between the EPOR and the β common receptor [9, 14] . The TPR is typically not highly expressed but compartmentalized intracellularly and is up-regulated and exposed when insult, trauma, hypoxia, and inflammation invoke subsequent tissue protection [9] . It also has a much lower EPO affinity and needs as high as fivefold systemic EPO levels to be activated[9]. EPO's tissue protective, tissue regenerative, angiogenetic, anti-inflammatory, and anti-apoptotic effects have been documented via exogenous EPO administration in both vertebrates and invertebrates and in a variety of disease models [11, 15, 16] and correlates to the expression of the EPOR in those nonhematopoietic tissues [11] . EPO via EPOR expressed on various immune cells, can directly affect the way immune cells exert their immunoregulatory effects, and shift the function of the immune system towards suppression, swing the inflammatory response to immune tolerance, protect injured tissues from apoptosis, and promote wound healing[17]. EPO's immunoregulatory effects have been demonstrated in experimental autoimmune encephalomyelitis[18] and in Th17 cell-associated immunemediated kidney diseases via EPO binding to T cell-expressed EPOR inhibiting Th17 cell induction [19] . Furthermore, EPO's beneficial pleiotropic effects on alveolarcapillary barrier integrity in acute lung injury/acute respiratory distress syndrome (ARDS) have been proposed to be potentially mediated through EPO's anti-inflammatory, anti-apoptotic, anti-oxidative, pro-angiogenic and cytoprotective actions [20, 21] . Finally, EPO stimulates bone marrow endothelial progenitor cell mobilization possibly contributing to pulmonary endothelial repair through fusion with resident cells, paracrine effects, or combinations of both [20, 21] . October 26, 2021

Volume 13 Issue 10

As TPR has a much lower EPO affinity, local tissue concentrations need to be high to activate it [9] .High endogenous EPO, dissonantly elevated from what is expected by a concurrent anemic stimulus and presumably to exert its non-erythropoietic tissue protective functions, has been reported in few studies [22] [23] [24] [25] . In all these situations, an imminent tissue insult or pathogen invasion are present while young age (< 13 years) appears to be an important and independent determinant of EPO response unrelated to the circulating hemoglobin levels ( Figure 1 ) [22] [23] [24] [25] . Cord blood EPO levels are strongly correlated to cord blood bilirubin in pathological neonatal hyperbilirubinemia potentially shielding the newborn brain from an imminent kernicterus[23]. In extremely premature newborns, elevated endogenous EPO levels varied with circulating levels of inflammation-related proteins possibly mediating protective and repair mechanisms [24] . As a response to pathogen invasion, younger children at all degrees of severe malarial anemia (SMA), tends to have significantly higher EPO levels than expected from their degree of anemia, a phenomenon that declines with increasing age [25] . That the maximum EPO response in SMA occurred very early and at a time when cerebral malaria is uncommon reinforces the notion of an appropriate tissue protective role for EPO [25] . In that sense, the emergence of the two specific classes of malaria protective genetic determinants (the thalassemias and the ACE D allele) is congruent with the evolutionary objective of augmenting either systemic and/or local tissue EPO concentrations to mitigate tissue injury and/or pathogen invasion. 

The above findings and the presence of EPO-like signaling involved in neuroprotection in insects that lack hematopoiesis[38], reinforce the rational assumption that, in younger age groups, high EPO levels could mediate a phylogenetically preserved ancestral neuroprotective innate immune response mechanism preventing lethal cerebral damage from both non-communicable (kernicterus, prematurity)[23,24] and communicable insults (cerebral malaria) ( Figure 1) 

RAS and Ang II effects demonstrate impressive complexity (Figure 2) [30,31]. First, in severe acute respiratory syndrome (SARS) and COVID-19 most deaths occur due to ARDS [63] . The frequency of the ACE D allele was reported to be significantly higher in ARDS[64] but also in the hypoxemic group in Vietnamese patients with SARS related ARDS in the first SARS epidemic [65] . The association of the ACE D allele/DD genotype with increased mortality is now being increasingly reported in various ethnic groups in SARS-CoV-2 as well [59, 66] . This association might reflect the effects the ACE D allele exerts via Ang II on interleukin 6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1) levels ( Figure 2) immune system towards a protracted course with aberrant gastrointestinal immune reactivity and endocrine autoimmunity including polyglandular autoimmune syndromes [96] [97] [98] . Moreover, it has been reported that in acute sarcoidosis presenting with erythema nodosum and usually a benign and self-restricting course, the ACE DD genotype, significantly worsens prognosis [99] . Caspase-1 mediated pyroptosis and autoantigen exposure could lead to AT1R autoantibodies[94], shown to correlate significantly with IL-6 [100] , that can further mediate persistent proinflammatory Ang II effects by agonistic stimulation of AT1 receptors and increased AT1 receptor activity, even in the absence of the ACE D allele. Low-dose acetylsalicylic acid (ASA) [101] and increasing bioactive lipid (BAL) intake [arachidonic acid (20:4 n-6), eicosapentaenoic acid (20:5 n-3), and docosahexaenoic acid (22:6 n-3)] may result in the formation of increased amounts of endogenous Lipoxin A4 (LXA4) thus offering novel treatment options in the prevention and management of COVID-19 ( Figure 2) [102] . Drug design research using LXA4 as a lead compound might result to innovative treatment modalities in autoimmune diseases [94] .

Second, RAS influence on EPO levels likely represents an amalgam of complex, intercalated and interrelated set of signals involving multiple molecular mechanisms [12,32, [103] [104] [105] [106] . Endogenously elevated EPO levels due to hypoxia in high altitude [107, 108] or in human genetic models seem protective [109] while low EPO levels are associated with dismal COVID-19 prognosis (Figure 1)[41] . Epidemiological studies suggest that physiological adaptation in a hypoxic environment at high altitude may protect persons from the severe impact of acute infection caused by SARS-CoV-2 [107, 108] . Reductions in cumulative incidence and mortality rates of COVID-19 with increasing altitude have been reported [107, 108] . Possible explanations are related to reduced virulence and decreased SARS-CoV-2 pathogenicity at high altitude [107] along with physiological acclimatization to chronic hypoxia via increased EPO and genetically adapted high altitude native populations with lower ACE DD genotype frequency [108, 110] . Recently, patients with fatal COVID-19 at 4150 meters above sea level displayed 2.5 times lower EPO levels compared to survivors but Ang II levels were not measured in that study [41] .

Furthermore, studies in patients with inherited genetic defects in specific kidney transporters and ion channels such as Gitelman's and Bartter's Syndromes (GS/BS) showed a statistically significant absence of COVID-19 infection and COVID-19 symptoms (Figure 1) [109] . In GS/BS patients, the above-mentioned genetic defects result in defective salt reabsorption in the thick ascending limb of loop of Henle [109] . The resulting salt wasting, hypokalemia, and metabolic alkalosis with relatively low levels of serum chloride induce chronic RAS activation with elevated Ang II levels but due to AT1R signaling defects a hypertensive phenotype is not seen [111] . Instead, endogenously increased levels of aberrantly glycosylated ACE2[112] and Ang 1-7 counteract Ang II effects [109, 112] . Intriguingly, GS/BS patients also demonstrate Ang II receptor type 2 dependent increase in EPO levels [103] and lack of Ang II induced increase of the PAI-1 gene and protein expression compared to healthy adults [113] , both phenomena being possibly protective against COVID-19 at any age.

In critical and deceased COVID-19 patients, EPO levels have recently been reported to be significantly lower and not in accordance with the similarly low hemoglobin levels [40, 41] . Moreover, elevated Ang II levels, strongly associated with viral load and lung injury have been reported in another study [84] , and in avian influenza A virus H5N1 infected mice and H7N9 infected patients [82, 83] . To date, no study has been reported in COVID-19 patients that has investigated the simultaneous measurement of Ang II and EPO and/or correlations to their ACE I/D polymorphism.

Renin and Ang II increase and RAS inhibitors inhibit EPO secretion in healthy volunteers [106] . Severe COVID-19 is also frequently associated with HT, DM, obesity, and metabolic syndrome [114] , all resulting in RAS activation through various mechanisms [106] . Nevertheless, the expected Ang II induced EPO rise does not occur in critically ill COVID-19 patients even though the RAS augmenting ACE D allele may be overrepresented in both COVID-19 and associated risk diseases[58,59,61]. Marathias et al [106] recently elegantly reviewed RAS and Ang II influence on EPO secretion. Glucose and sodium reabsorption, hyperinsulinemia, the G-protein-coupled receptor 91, all induce RAS activation. The increased Ang II is expected to enhance EPO secretion through tubulointerstitial ischemia, direct upregulation of EPO transcription factors and bone marrow stimulation along with enabling erythropoiesis supportive iron metabolism [106] . On the other hand, glucose toxicity in the renal parenchyma in concurrent DM, obesity, and metabolic syndrome, induce damage on the renal EPO-producing cells and lower EPO secretion. Additionally, HT with widespread use of RAS inhibitors, diabetic hyporeninemic hypoaldosteronism, autonomic neuropathy, obesity or DM induced hypogonadism with low testosterone, chronic and acute inflammation through Ang II induced IL-6 increase[72], all inhibit renal EPO secretion (Figure 2) [71, 106] . Finally, blunted EPO response has been documented in critically ill patients while a recent meta-analysis suggests that EPO therapy may decrease mortality [115] .

Moreover, elevated Ang II reduces renal α-Klotho expression, interfering with FGF23 signaling and resulting in elevated FGF23 Levels (Figure 2 ) [116] . FGF23 will inhibit 1α-hydroxylase, leading to the lowering of 1,25-dihydroxyvitamin D3 production and cause or aggravate an incipient vitamin D deficiency, implicated in numerous adverse outcomes including morbidity and mortality in COVID-19 [116, 117] . All the ACE D allele associations as in HT, type 2 DM, kidney disease, and possibly mortality in COVID-19 could be explained by Ang II induced FGF23 elevations [84, 116] . FGF23 serves as a proinflammatory paracrine factor, secreted mainly by M1 proinflammatory macrophages [118] . Powerful and dose-dependent associations have been demonstrated between elevated FGF23 Levels and higher risks for chronic kidney disease, left ventricular hypertrophy and congestive heart failure, autosomal dominant hypophosphatemic rickets, osteomalacia, vitamin D deficiency, fibrous dysplasia, aging, and mortality [119] . Unifying these mechanisms is the finding that both IL-6 and PAI-1 are significant regulators of FGF23 homeostasis[119-121]. Dexamethasone abolished IL-6 induced FGF23 increase[119,120] while PAI-1 inhibition substantially decreased FGF23 levels ( Figure 2) [121]. rhEPO administration significantly decrease PAI-1 levels in multi-trauma patients [122] and led to the miraculous recovery of a critically ill elderly COVID-19 patient[123]. EPO's inhibitory effect on PAI-1 and subsequently FGF23 may well have contributed to the patient's recovery and further studies are planned to investigate the potentially favorable rhEPO effect in severe COVID-19 [124] [125] [126] . Human data show that both endogenous and exogenous EPO influence FGF23 levels via alterations of the ratio of active to inactive FGF23 in favor of its inactive form, thus attenuating effects of bioactive intact FGF23 levels and explain EPO's protective effects [118, 127] . At present, no study has been reported that investigated FGF23 levels in COVID-19. October 26, 2021

Volume 13 Issue 10

Currently, therapeutic approaches are symptomatic and include empirical immunosuppressive and anti-inflammatory tactics (dexamethasone) [128] , interferons [129] , targeting of individual cytokines (IL-6: Tocilizumab/statins/heparin; PAI-1: Statins, and numerous target substances in development)[75, [130] [131] [132] and correction of isolated laboratory abnormalities (e.g., sodium disturbances) [133] . Prolonged use of these interventions may lead to serious adverse effects and reduction of host defenses with resurgence of opportunistic infections. An Occam's razor therapeutic strategy guided by mendelian, and mechanistic evidence might be pursued. ACE I/D polymorphism genetic testing could be predictive and guide patient triage and treatment decision making as individuals with the DD genotype are predisposed to a more severe COVID-19 disease course [59] . Research evidence supports the notion that endogenously [109, 112] and exogenously increased EPO levels[123] could break the vicious circle of persistent ACE D allele augmented Ang II stimulation on PAI-1, IL-6 and FGF23 by both synergistic and individual inhibition [21, 122, 123, 127, 134] . Whenever the administration of rhEPO is not possible due to contraindications or heightened prothrombotic risk, EPO derivatives can coax EPO's tissue-protective activity via its TPR for therapeutic use without the risks attributed to EPO's hematological actions[10,14,134]. Furthermore, EPO mediates reduction of auto-and alloantibody formation and used together with LXA4 inducing BALs and/or ASA could prevent recently reported AT1-AA induced collateral damage and autoimmune pathology [94, 101, 102, 135, 136] . Moreover, in hematologic patients, rhEPO treatment is associated with an enhanced antibody response to the influenza vaccine, similar to that of healthy subjects and it is conceivable that this effect could also be replicated in COVID-19 vaccinations, especially in immunocompromised patients [137] . Additional treatment modalities could employ a combination of autologous peripheral blood or umbilical cord-derived mesenchymal stromal cells and rhEPO/EPO derivatives that induce notable clinical improvement shortly after initiating treatment in a critically ill patient with severe ARDS [138, 139] .

Recently, NP-6A4, a novel AT2R peptide agonist with an FDA orphan drug designation for pediatric cardiomyopathy, increased expression of AT2R and cardioprotective EPO in a pre-clinical model with severe obesity and pre-diabetes (ZO rat), along with suppression of nineteen inflammatory cytokines including IL-6 without increasing expression levels of ACE2 [140] . NP-6A4 appears as an ideal adjuvant drug candidate for EPO mediated tissue protection and mitigation of cytokine storm [140] . Finally, elucidating FGF23 Levels in COVID-19 could help prognosticate, prevent, and help treat potential future complications. The use of FGF23 antagonists such as the FGF23 antibody burosumab, could be employed to lower FGF23 Levels in FGF23-mediated disorders [141] , including COVID-19. To date and to the authors' knowledge, such clinical trials do not exist.

Age dependent EPO secretion[22-25] and the contribution of EPO augmenting genetic determinants in children and adults as a disease modifier in malaria is established[6, 25-28]. In the present work, we posit that this EPO effect extends to and explains COVID-19 protection in children[39] and can provide new pathophysiological insights and therapeutic avenues in adults (Figure 1 ). Elevated protective EPO mRNA levels were recently reported being 2.6 times higher in nasopharyngeal swab samples of adult SARS-CoV-2 patients that were asymptomatic or showing mild COVID-19 clinical symptoms, as compared to a control group [142] . EPO induces endothelial nitric oxide (NO) synthase and increases NO production in endothelial cells [14] . Increased NO bioavailability is shown to inhibit fusion of the SARS-CoV spike protein to ACE2 and early production of viral RNA [143], potentially mediating EPO protection in SARS-CoV-2 too.

The intricate balance between the components of the RAS axis (peptides and peptidases) and its interactions with the EPO and α-Klotho/FGF23 axes are incompletely understood in the context of chronic stable and acute decompensated environments. Known and potentially reduce EPO levels in critically ill COVID-19 adult patients (Figure 2 ) [40, 41] . In adults with COVID-19, this proinflammatory constellation would promote progress to ARDS, and cytokine storm with pyroptotic inflammatory reactions, autoantigen exposure, autoantibody production and subsequent autoimmune disorders [95] .

worldwide COVID-19 cases and deaths

SARS-CoV-2, the autoimmune virus

Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases

High frequency of endocrine autoimmunity in patients with sarcoidosis

Evidence of gastrointestinal immune reactivity in patients with sarcoidosis

The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients

Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes

The 15-Epilipoxin-A4 Pathway with Prophylactic Aspirin in Preventing Preeclampsia: A Longitudinal Cohort Study

Bioactive Lipids in COVID-19-Further Evidence

Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism

Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors

Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes

Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?

Incidence of COVID-19 infection and prevalence of diabetes, obesity and hypertension according to altitude in Peruvian population

ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes

The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with adaptation to high altitude: A meta-analysis

ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications

Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?

Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling

] agents in critically ill patients admitted to the intensive care unit: a systematic review and metaanalysis

Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition

Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19

Effects of erythropoietin on fibroblast growth factor 23 in mice and humans

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease

PAI-1 is a critical regulator of FGF23 homeostasis

Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-inflammatory responses following trauma

Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects

Erythropoietin as candidate for supportive treatment of severe COVID-19

A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19

Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis

Dexamethasone in Hospitalized Patients with Covid-19

Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials

Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19

COVID-19: Direct and Indirect Mechanisms of Statins

Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU?

Serum sodium alterations in SARS CoV-2 (COVID-19) infection: impact on patient outcome

Potential anti-inflammatory effect of erythropoietin in nonclinical studies in vivo: A systematic review

Erythropoietin Reduces Auto-and Allo-Antibodies By Inhibiting T Follicular Helper Cell Differentiation

Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19

Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients

Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome

The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia

Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4

Upstream Regulators of Fibroblast Growth Factor 23

Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform

Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected